Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 12, 2018

Primary Completion Date

May 3, 2019

Study Completion Date

May 3, 2019

Conditions
Amyloidosis
Interventions
DRUG

GSK3039294

GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.

DRUG

Placebo

Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.

Trial Locations (1)

NW10 7EW

GSK Investigational Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03567499 - Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects | Biotech Hunter | Biotech Hunter